Oxford BioMedica swings into profit

Oxford BioMedica swings into profit

Last time we wrote about Oxford BioMedica (OXB), we expressed concern about its reliance on Novartis. The group earns almost all its revenues by providing the Swiss pharma giant with the delivery mechanism for its gene editing cancer therapy, Kymriah. Since then, Oxford BioMedica’s lentiviral technology has caught the attention of more leading pharmaceutical companies, handing the group two further contracts, which contributed £20.6m to gross income in the first half of 2018.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now